LadRx Corporation

0.0014

-0.1021-98.65%

Volume:106.00

Turnover:0.20

Market Cap:693.13

PE:0.00

High:0.0014

Open:0.0014

Low:0.0014

Close:0.1035

52wk High:2.40

52wk Low:0.0001

Shares:495.09K

Float Shares:485.73K

Volume Ratio:5.96

T/O Rate:0.02%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-5.0409

EPS(LYR):-3.2109

ROE:-653.73%

ROA:-176.86%

PB:-0.00

PE(LYR):0.00

Loading ...

Overview Company News Filings

Concept

No relevant data is available

Capital Flow

Inflow:

Outflow:

News

LadRx Corporation Announces Intent to Seek FDA Marketing Approval for Aldoxorubicin Despite Resource Limitations

Reuters

·

Jun 27, 2025

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/LADX"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"LADX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LADX\",,,,,undefined,":{"symbol":"LADX","market":"US","secType":"STK","nameCN":"LadRx Corporation","latestPrice":0.0014,"timestamp":1771621200000,"preClose":0.1035,"halted":0,"volume":106,"delay":15,"changeRate":-0.9864734299516909,"floatShares":485728,"shares":495092,"eps":-5.040903,"marketStatus":"Market Closed","change":-0.1021,"latestTime":"02-20 16:00:00 EST Delay","open":0.0014,"high":0.0014,"low":0.0014,"amount":0.1972,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":-5.040903,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1771837200000},"marketStatusCode":7,"adr":0,"exchange":"EXPERT","adjPreClose":0.1035,"volumeRatio":5.95505952531434},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LADX\",,,,,undefined,":{"symbol":"LADX","floatShares":485728,"roa":"-176.86%","roe":"-653.73%","lyrEps":-3.210888,"volumeRatio":5.95505952531434,"shares":495092,"dividePrice":0,"high":0.0014,"amplitude":0,"preClose":0.1035,"low":0.0014,"week52Low":0.0001,"pbRate":"-0.00","week52High":2.4,"institutionHeld":0,"latestPrice":0.0014,"eps":-5.040903,"divideRate":0,"volume":106,"delay":15,"ttmEps":-5.040903,"open":0.0014,"prevYearClose":0.011,"prevWeekClose":0.1035,"prevMonthClose":0.1035,"prevQuarterClose":0.011,"fiveDayClose":0.1035,"twentyDayClose":0.1035,"sixtyDayClose":0.13},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/LADX\",params:#limit:5,,,undefined,":[{"market":"US","date":"2024-11-14","symbol":"LADX","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1731560400000,"reportTimeType":"pre","actualEps":null},{"market":"US","date":"2024-08-14","symbol":"LADX","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1723608000000,"reportTimeType":"pre","actualEps":null},{"market":"US","date":"2024-05-15","symbol":"LADX","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1715745600000,"reportTimeType":"pre","actualEps":null},{"market":"US","date":"2024-03-27","symbol":"LADX","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1711512000000,"reportTimeType":"pre","actualEps":null},{"market":"US","date":"2023-11-14","symbol":"LADX","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1699938000000,"reportTimeType":"pre","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"LADX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"LADX\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"LADX\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2546147327","title":"LadRx Corporation Announces Intent to Seek FDA Marketing Approval for Aldoxorubicin Despite Resource Limitations","url":"https://stock-news.laohu8.com/highlight/detail?id=2546147327","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546147327?lang=en_us&edition=fundamental","pubTime":"2025-06-27 18:09","pubTimestamp":1751018943,"startTime":"0","endTime":"0","summary":"LadRx Corporation announced on December 11, 2024, its intent to approach the Food and Drug Administration  with a proposal to seek marketing approval for aldoxorubicin under section 505 using existing clinical and supplemental non-clinical data. However, after further research and review, the company has concluded that while obtaining this approval is possible, it currently lacks the necessary resources to undertake the activities required for the approval process. No additional information on grants or funding from other organizations has been provided.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. LadRx Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250627:nNDL1lScyJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LADX"],"gpt_icon":0}],"pageSize":4,"totalPage":1,"pageCount":1,"totalSize":1,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/LADX\",params:#limit:6,delay:false,,,undefined,":[]}}